The drug Pazopanib may be effective in treating bone cancer. This is demonstrated by a clinical case published in the journal. oncoscience.
Scientists reported the case of a previously healthy man who presented with a mass in his left leg at the age of 30. He was diagnosed with sarcoma (a type of cancer) of the bone. Two years after treatment, he was diagnosed with metastases in the lungs and heart, which were surgically removed. 16 months later, metastases were found again in his lungs, which were surgically removed along with part of his lungs.
There are numerous reports regarding the possible effectiveness of pazopanib in the treatment of bone sarcomas. Therefore, doctors and the patient decided to try taking this medicine every day. According to the publication’s authors, the man’s disease remained under control for five years, after which they decided to stop taking Pazopanib. A few months later, the patient had metastases in his lungs again. The patient’s cancer did not recur for 30 months after it was taken, and today the man continues to live without medication.
Pazopanib was initially approved for the treatment of kidney cancer and soft tissue sarcoma. However, there is limited evidence of its benefit in bone sarcomas. The authors believe that the clinical case they describe confirms the promising efficacy of Pazopanib in preventing and slowing bone cancer metastasis.
used to be a doctor saidHow to prevent 99% of dangerous cancer cases.